'''Perlapine''', sold under the brand names '''Hypnodine''' and '''Pipnodine''', is a [[hypnotic]] and [[sedative]] of the [[tricyclic compound|tricyclic]] group which is marketed in [[Japan]].<ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA811|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=811–}}</ref> It acts primarily as a [[potency (pharmacology)|potent]] [[antihistamine]],<ref name="Lajtha2013">{{cite book|author=Abel Lajtha|title=Alterations of Metabolites in the Nervous System|url=https://books.google.com/books?id=dYnSBwAAQBAJ&pg=PA352|date=11 November 2013|publisher=Springer Science & Business Media|isbn=978-1-4757-6740-7|pages=352–}}</ref> and also has [[anticholinergic]],<ref name="Lajtha2013" /> [[antiserotonergic]],<ref name="Elsevier1996">{{cite book|title=Progress in Medicinal Chemistry|url=https://books.google.com/books?id=SDaZ4qcemf8C&pg=PA226|date=24 April 1996|publisher=Elsevier|isbn=978-0-08-086281-1|pages=226–}}</ref> [[antiadrenergic]], and some [[antidopaminergic]] activity.<ref name="Elsevier1996" /><ref name="Hathway2007">{{cite book|author=D E Hathway|title=Foreign Compound Metabolism in Mammals|url=https://books.google.com/books?id=UHAoDwAAQBAJ&pg=PA302|date=31 October 2007|publisher=Royal Society of Chemistry|isbn=978-1-84755-608-0|pages=302–}}</ref><ref name="Publishers1995">{{cite book|author=Bentham Science Publishers|title=Current Medicinal Chemistry|url=https://books.google.com/books?id=eMw2LsjQ5PQC&pg=PA489|date=April 1995|publisher=Bentham Science Publishers|pages=489–}}</ref><ref name="Barnes2013">{{cite book|author=Thomas R.E. Barnes|title=Antipsychotic Drugs and Their Side-Effects|url=https://books.google.com/books?id=IT2OAgAAQBAJ&pg=PA34|date=22 October 2013|publisher=Elsevier Science|isbn=978-1-4832-8810-9|pages=28,34}}</ref> The drug has relatively weak [[affinity (pharmacology)|affinity]] for the [[dopamine]] [[D2 receptor|D<sub>2</sub> receptor]] ({{abbrlink|IC<sub>50</sub>|Half-maximal inhibitory concentration}} = 1,803&nbsp;nM) and, in accordance, is said to be ineffective as an [[antipsychotic]].<ref name="Barnes2013" /><ref name="Neuropsychopharmacology1978">{{cite book|author=American College of Neuropsychopharmacology|title=Psychopharmacology: a generation of progress|url=https://books.google.com/books?id=c-RsAAAAMAAJ|year=1978|publisher=Raven Press|isbn=978-0-89004-191-8|page=514}}</ref> However, it retains higher affinity for the dopamine [[D1 receptor|D<sub>1</sub> receptor]] ({{abbr|IC<sub>50</sub>|Half-maximal inhibitory concentration}} = 198&nbsp;nM).<ref name="Barnes2013" /> Its {{abbr|IC<sub>50</sub>|Half-maximal inhibitory concentration}} values are 19&nbsp;nM for the [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]], 4,945&nbsp;nM for the [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic recpetor]], and 70&nbsp;nM for the [[serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]].<ref name="Barnes2013" /> Perlapine is closely related to [[clotiapine]], [[clozapine]], [[fluperlapine]], [[loxapine]], and [[tilozepine]].<ref name="Barnes2013" />
